NCCN Recommendation as a Category 1 Treatment Option
Liposomal irinotecan (ONIVYDE®) + 5-FU/LV is the only Category 1 option for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression1
|Tumor type||Line of therapy||NCCN
|Line of therapy||Second-line, with
|5-FU + leucovorin +
for patients with
cancer who have a
ECOG=Eastern Cooperative Oncology Group; PS=performance status.
*ECOG 0-1, patent biliary stent, and adequate nutritional intake.
Therapies are categorized on the following rating system based on National Comprehensive Cancer Network® (NCCN®) categories of evidence and consensus. 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate; 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. All recommendations are category 2A unless otherwise noted.